Department of Oncology, The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
Nucl Med Biol. 2012 Aug;39(6):756-62. doi: 10.1016/j.nucmedbio.2012.02.003. Epub 2012 Mar 24.
In peptide receptor radionuclide therapy for neuroendocrine tumors the main dose-limiting tissue is found in the kidneys because of tubular reabsorption and retention of radioactivity. The aim of this study was to quantify late effects in renal cortex of nude mice exposed to high amounts of [(177)Lu]-DOTA-Tyr(3)-octreotate ([(177)Lu]-DOTATATE), and to determine whether a threshold dose value exists for these findings.
Nude mice were exposed to 90, 120 or 150 MBq of [(177)Lu]-DOTATATE. Renal toxicity was evaluated up to 6 months after injection. Blood samples were collected to examine renal functional markers, and after sacrifice at 6 months changes in renal morphology were explored. Tissue damage was estimated by quantifying the relative area of the different subunits in the renal cortex using point counting. Additional morphological signs of radiation damage were also noted. The absorbed doses to the kidneys were estimated by previously determined kidney pharmacokinetics and Monte Carlo simulations for different assumptions regarding the activity distribution.
Increased serum creatinine and urea values indicated long-term renal toxicity. The tissue area occupied by proximal tubules decreased with increasing doses of [(177)Lu]-DOTATATE, whereas the other subunits in cortex slightly increased. The mean absorbed dose in the renal cortex for [(177)Lu]-DOTATATE was estimated to be 35-58 Gy for the different groups of animals. A dose-response relationship was observed for proximal tubular damage, and a threshold dose value of 24 Gy (BED 37 Gy) was determined.
Selective morphological changes in kidney cortex of nude mice were quantified and appeared in a dose dependent manner after injection of high amounts of [(177)Lu]-DOTATATE.
在神经内分泌肿瘤的肽受体放射性核素治疗中,由于放射性物质的肾小管重吸收和滞留,肾脏是主要的剂量限制组织。本研究的目的是定量研究大量[(177)Lu]-DOTA-Tyr(3)-奥曲肽([(177)Lu]-DOTATATE)暴露的裸鼠肾皮质的晚期效应,并确定是否存在这些发现的剂量阈值。
裸鼠暴露于 90、120 或 150MBq 的[(177)Lu]-DOTATATE。注射后 6 个月内评估肾毒性。采集血样以检查肾功能标志物,6 个月后处死时探索肾形态变化。通过使用点计数定量评估肾皮质不同亚单位的相对面积来估计组织损伤。还注意到了其他形态学的辐射损伤迹象。通过先前确定的肾脏药代动力学和蒙特卡罗模拟,根据不同的活动分布假设,估算肾脏的吸收剂量。
血清肌酐和尿素值升高表明存在长期肾毒性。随着[(177)Lu]-DOTATATE 剂量的增加,近端小管所占的组织面积减少,而皮质的其他亚单位略有增加。[(177)Lu]-DOTATATE 在肾皮质的平均吸收剂量估计为不同组动物的 35-58Gy。观察到近端肾小管损伤的剂量反应关系,并确定了 24Gy(BED 37Gy)的阈值剂量值。
在注射大量[(177)Lu]-DOTATATE 后,裸鼠肾皮质的选择性形态变化被定量,并呈剂量依赖性出现。